Fig. 5
From: Multi-scale characterisation of homologous recombination deficiency in breast cancer
HRD transcriptional signature is linked with PARP inhibitor sensitivity in breast cancer cell lines and patients. a Correlation between the HRD transcriptional scores calculated using transcriptomes from breast cancer cell lines from CCLE and sensitivity to PARP inhibitors evaluated using the PRISM metric. b Comparison of HRD transcriptional scores between responders and non-responders to olaparib and durvalumab combination treatment in the I-SPY2 trial. c Correlation of HRD transcriptional scores against the PARPi7 signature score calculated by Pusztai et al. (38) in the I-SPY2 treatment arm patients. Responders are more frequently scoring high using our signature compared to PARPi7